198 related articles for article (PubMed ID: 37925511)
21. Tislelizumab immunotherapy combined with chemotherapy in the treatment of a patient with primary anterior mediastinal undifferentiated pleomorphic sarcoma with high PD-L1 expression: A case report and literature review.
Yang H; Qin Z; He X; Xue Q; Zhou H; Sun J; Li X; Zhao T
Front Oncol; 2023; 13():1110997. PubMed ID: 37091183
[TBL] [Abstract][Full Text] [Related]
22. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.
Conley AP; Wang WL; Livingston JA; Ravi V; Tsai JW; Ali A; Ingram DR; Lowery CD; Roland CL; Somaiah N; Hwu P; Yee C; Subbiah V; Futreal A; Lazar AJ; Patel S; Roszik J
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31096717
[TBL] [Abstract][Full Text] [Related]
23. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
24. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL
Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085
[TBL] [Abstract][Full Text] [Related]
25. Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
Crago AM; Cardona K; Koseła-Paterczyk H; Rutkowski P
Surg Oncol Clin N Am; 2022 Jul; 31(3):419-430. PubMed ID: 35715142
[TBL] [Abstract][Full Text] [Related]
26. The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade.
Hildebrand KM; Singla AK; McNeil R; Marritt KL; Hildebrand KN; Zemp F; Rajwani J; Itani D; Bose P; Mahoney DJ; Jirik FR; Monument MJ
PLoS One; 2021; 16(7):e0253864. PubMed ID: 34242269
[TBL] [Abstract][Full Text] [Related]
27. Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes.
Winchester D; Lehman J; Tello T; Chimato N; Hocker T; Kim S; Chang J; Markey J; Yom SS; Ryan W; Mully T; Hodge D; Otley C; Arron ST
J Am Acad Dermatol; 2018 Nov; 79(5):853-859. PubMed ID: 29787841
[TBL] [Abstract][Full Text] [Related]
28. PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.
Boxberg M; Steiger K; Lenze U; Rechl H; von Eisenhart-Rothe R; Wörtler K; Weichert W; Langer R; Specht K
Oncoimmunology; 2018; 7(3):e1389366. PubMed ID: 29399389
[TBL] [Abstract][Full Text] [Related]
29. Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial.
Miwa S; Nojima T; Alomesen AA; Ikeda H; Yamamoto N; Nishida H; Hayashi K; Takeuchi A; Igarashi K; Higuchi T; Yonezawa H; Araki Y; Morinaga S; Asano Y; Tsuchiya H
Clin Transl Oncol; 2021 Aug; 23(8):1620-1629. PubMed ID: 33635466
[TBL] [Abstract][Full Text] [Related]
30. Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening.
Kiyuna T; Murakami T; Tome Y; Igarashi K; Kawaguchi K; Russell T; Eckardt MA; Crompton J; Singh A; Bernthal N; Bukata S; Federman N; Kanaya F; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Feb; 118(2):361-365. PubMed ID: 27357060
[TBL] [Abstract][Full Text] [Related]
31. New established cell lines from undifferentiated pleomorphic sarcoma for in vivo study.
Lee EY; Kim YH; Rayhan MA; Kang HG; Kim JH; Park JW; Park SY; Lee SH; You HJ
BMB Rep; 2023 Apr; 56(4):258-264. PubMed ID: 36789562
[TBL] [Abstract][Full Text] [Related]
32. Radiation Therapy Combined With Checkpoint Blockade Immunotherapy for Metastatic Undifferentiated Pleomorphic Sarcoma of the Maxillary Sinus With a Complete Response.
Guram K; Nunez M; Einck J; Mell LK; Cohen E; Sanders PD; Miyauchi S; Weihe E; Kurzrock R; Boles S; Sharabi AB
Front Oncol; 2018; 8():435. PubMed ID: 30386736
[No Abstract] [Full Text] [Related]
33. PD-L1 expression in sarcomas: An immunohistochemical study and review of the literature.
Cunningham CR; Dodd L; Esebua M; Layfield LJ
Ann Diagn Pathol; 2021 Dec; 55():151823. PubMed ID: 34656856
[TBL] [Abstract][Full Text] [Related]
34. Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy.
Li Y; Liu Y; Qu Y; Chen X; Qu X; Ye Y; Du X; Cheng Y; Xu M; Zhang H
Front Immunol; 2022; 13():832593. PubMed ID: 35603147
[TBL] [Abstract][Full Text] [Related]
35. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.
Keung EZ; Tsai JW; Ali AM; Cormier JN; Bishop AJ; Guadagnolo BA; Torres KE; Somaiah N; Hunt KK; Wargo JA; Lazar AJ; Wang WL; Roland CL
Oncoimmunology; 2018; 7(2):e1385689. PubMed ID: 29308306
[No Abstract] [Full Text] [Related]
37. Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas.
Hashimoto K; Nishimura S; Ito T; Akagi M
Eur J Histochem; 2021 Jul; 65(3):. PubMed ID: 34218652
[TBL] [Abstract][Full Text] [Related]
38. HLA-restricted specific tumor cytolysis by autologous T-lymphocytes infiltrating metastatic bone malignant fibrous histiocytoma of lymph node.
Tsukahara T; Kawaguchi S; Ida K; Kimura S; Tamura Y; Ikeda T; Torigoe T; Nagoya S; Wada T; Sato N; Yamashita T
J Orthop Res; 2006 Jan; 24(1):94-101. PubMed ID: 16419974
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy for sarcomas.
Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in Sarcoma: Where Do Things Stand?
Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A
Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]